Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down
In This Article:
Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.